Treatment Toxicity: Radiation
Thomas J. FitzGerald(University of Massachusetts Chan Medical School), David J. Goff(University of Massachusetts Chan Medical School), L.N. Shanmugham(University of Massachusetts Chan Medical School), Beth Herrick(University of Massachusetts Chan Medical School), A.L. Elaimy(University of Massachusetts Chan Medical School), Alexander Lukez(Dana-Farber Cancer Institute), Maryann Bishop‐Jodoin(Health Insurance Review and Assessment Service), Jon Glanzman(University of Massachusetts Chan Medical School), Peter Lee(Research Complex at Harwell), Fran Laurie(University of Massachusetts Chan Medical School), Matthew Iandoli(Calista Therapeutics (United States)), James Shen
Cited by 1
Related Papers
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
|Journal of Clinical Oncology|2010|806
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|601
Operando Visualization and Multi-scale Tomography Studies of Dendrite Formation and Dissolution in Zinc Batteries
|Joule|2018|451
Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial
|Journal of Clinical Oncology|2014|394
Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma—a report from the IRSG 1 1For a complete list of the members of the Children’s Oncology Group Soft Tissue Sarcoma Committee (formerly Intergroup Rhabdomyosarcoma Group) representing the Children’s Oncology Group and the Quality Assurance Review Center, see the Appendix.
|International Journal of Radiation Oncology*Biology*Physics|2001|213